565 related articles for article (PubMed ID: 34634427)
1. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
[TBL] [Abstract][Full Text] [Related]
2. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
[TBL] [Abstract][Full Text] [Related]
3. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
Ibing S; Cho JH; Böttinger EP; Ungaro RC
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
[TBL] [Abstract][Full Text] [Related]
4. Role of ustekinumab in treatment of ulcerative colitis: a narrative review.
Grova M; Vitello A; Mannino M; Casà A; Renna S; Macaluso FS; Orlando A
Immunotherapy; 2023 Dec; 15(18):1539-1552. PubMed ID: 38018475
[TBL] [Abstract][Full Text] [Related]
5. Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases.
Cheng D; Kochar BD; Cai T; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2366-2372.e6. PubMed ID: 35066137
[TBL] [Abstract][Full Text] [Related]
6. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
7. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
Aliment Pharmacol Ther; 2024 Jun; 59(11):1312-1334. PubMed ID: 38651771
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
[TBL] [Abstract][Full Text] [Related]
11. Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB.
Fróes RSB; Andrade AR; Faria MAG; de Souza HSP; Parra RS; Zaltman C; Dos Santos CHM; Bafutto M; Quaresma AB; Santana GO; Luporini RL; de Lima Junior SF; Miszputen SJ; de Souza MM; Herrerias GSP; Junior RLK; do Nascimento CR; Féres O; de Barros JR; Sassaki LY; Saad-Hossne R
Sci Rep; 2024 Feb; 14(1):4314. PubMed ID: 38383742
[TBL] [Abstract][Full Text] [Related]
12. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.
Berinstein EM; Sheehan JL; Jacob J; Steiner CA; Stidham RW; Shannon C; Bishu S; Levine J; Cohen-Mekelburg SA; Waljee AK; Higgins PDR; Berinstein JA
Dig Dis Sci; 2023 Jun; 68(6):2604-2623. PubMed ID: 36807832
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials.
Rolston VS; Kimmel J; Popov V; Bosworth BP; Hudesman D; Malter LB; Hong S; Chang S
Dig Dis Sci; 2021 May; 66(5):1631-1638. PubMed ID: 32445049
[TBL] [Abstract][Full Text] [Related]
17. Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
Tepeš K; Hanžel J; Štubljar D; Strmšek K; Erjavec L; Supovec E; Jagodic Z; Končan M; Grosek J; Košir JA; Tomažič A; Kogovšek U; Norčič G; Šibli R; Žnidaršič M; Pačnik Vižintin T; Sodin B; Breznik J; Hribar VA; Ocepek A; Pernat Drobež C; Bukovnik N; Zafošnik A; Marušič T; Jurečič Brglez N; Denkovski M; Smrekar N; Novak G; Koželj M; Kurent T; Simonič J; Pintar Š; Štabuc B; Drobne D
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):728-734. PubMed ID: 38625825
[TBL] [Abstract][Full Text] [Related]
18. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms.
Mocci G; Tursi A; Onidi FM; Usai-Satta P; Pes GM; Dore MP
J Clin Med; 2024 Mar; 13(5):. PubMed ID: 38592377
[TBL] [Abstract][Full Text] [Related]
19. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
[No Abstract] [Full Text] [Related]
20. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
